A Exploratory, Double-Blind, Randomized, Placebo-Controlled Trial to Investigate the Tissue Specific Effects of 2.5 mg Tibolone on Breast Cancer in Postmenopausal Women, in Particular on Breast Tissue Proliferation.

Trial Profile

A Exploratory, Double-Blind, Randomized, Placebo-Controlled Trial to Investigate the Tissue Specific Effects of 2.5 mg Tibolone on Breast Cancer in Postmenopausal Women, in Particular on Breast Tissue Proliferation.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jun 2017

At a glance

  • Drugs Tibolone (Primary)
  • Indications Early breast cancer; Menopause
  • Focus Pharmacodynamics; Pharmacokinetics
  • Acronyms STEM
  • Sponsors Organon
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Oct 2009 Additional lead trial centre and sponsor (Schering-Plough) identified as reported by ClinicalTrials.gov.
    • 21 Aug 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top